跳至主要内容
临床试验/IRCT20200727048226N1
IRCT20200727048226N1尚未招募2 期

Efficacy of Empagliflozin on cardiac function in non- diabetic patients after primary percutaneous angioplasty on left anterior descending coronary artery

Tehran University of Medical Sciences0 个研究点目标入组 88 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
88

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • non-diabetic patients with PPCI on LAD that are SVD: non-diabetic patients definition: 1-HbA1C<6.5 2-history of non-diabetes 3-twice FBS<100 if two of three of these exist patient is eligible for entery of trial

排除标准

  • 1-History of serious hypersensitivity to empagliflozin or any component of the formulation; -Severe renal impairment (eGFR <30 mL/minute/1.73 m2), end-stage renal disease (ESRD), or dialysis 2-patients that have more than one vessel disease or have SVD with non-culprit lesion >70% or with SVD of LCX or RCA 3-patients 4- diabetic patients

研究者

相似试验